Antibacterial action of visible 405-nm light for bacterial reduction in blood plasma

Stewart, Caitlin Fiona and Ralston, Heather and MacPherson, Ruairidh and Wilson, Mark and MacGregor, Scott and Atreya, Chintamani and Maclean, Michelle (2022) Antibacterial action of visible 405-nm light for bacterial reduction in blood plasma. Access Microbiology, 4 (5). ISSN 2516-8290 (https://doi.org/10.1099/acmi.ac2021.po0227)

[thumbnail of Stewart-etal-AM-2022-Antibacterial-action-of-visible-405-nm-light-for-bacterial-reduction]
Preview
 Text. Filename: Stewart_etal_AM_2022_Antibacterial_action_of_visible_405_nm_light_for_bacterial_reduction.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (886kB)| Preview

Abstract

The introduction of risk prevention measures, such as blood screening and donor deferrals have dramatically reduced the incidence of transfusion-transmitted viral infections. Nevertheless, bacterial contamination of blood transfusion products remains a concern to patient health, and a range of pathogen reduction technologies have been developed to reduce this risk. Visible violet-blue light, in the region of 405-nm, has recently demonstrated potential for in situ treatment of ex vivo stored plasma and platelet products, without the need for additional photosensitizers. This study assessed the broad-spectrum efficacy of 405-nm light against a range of bacteria implicated in transfusion-transmitted infections: Staphylococcus aureus, Staphylococcus epidermidis, Bacillus cereus, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniaeandYersinia enterocolitica. Plasma was seeded with clinically-relevant low-level bacterial contamination (102-103CFUmL-1) and exposed to a 405-nm light dose of 360 Jcm-2 (1-hr at 100mWcm-2) using a small-scale exposure system. Broad spectrum antibacterial efficacy was observed, with 99.0 – 100% inactivation achieved for all bacterial species tested. Bacterial inactivation tests were then scaled-up to expose large volumes of prebagged plasma seeded with S. aureusat ~103 CFUmL-1, to 22mWcm-2 405-nm light, under agitation, (≤396 Jcm-2). Successful bacterial inactivation was observed using the large-scale exposure system, with a dose of 238 Jcm-2 (3-hr at ~22mWcm-2) achieving complete (3.5-log10) reductions in prebagged bacterial-seeded plasma (P=0.001). Results from this study support further development of visible 405-nm light technology as a bactericidal tool for application in transfusion medicine. This abstract reflects the views of the author and should not be construed to represent FDA’s views or policies.

CORE (COnnecting REpositories)